Insmed Inc. Stock
Insmed Inc. Stock
Heavy losses for Insmed Inc. today as the stock fell by -€2.930 (-3.240%).
With 63 Buy predictions and 1 Sell predictions Insmed Inc. is one of the favorites of our community.
As a result the target price of 173 € shows a very positive potential of 97.71% compared to the current price of 87.5 € for Insmed Inc..
For the coming years our community has positive and negative things to say abot the Insmed Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Return on equity" there were negative voices in the community.
Pros and Cons of Insmed Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insmed Inc. | -3.240% | -6.974% | -6.146% | -4.891% | -40.878% | 362.963% | 324.757% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
When examining the financials of Insmed (INSM), a player in the Biotechnology & Medical Research sector, it's essential to approach the numbers with a blend of cautious optimism and critical scrutiny. Insmed shows significant promise in terms of market capitalization and revenue growth potential, but several challenges lurk beneath the surface, particularly regarding profitability and high debt levels. Let’s dig deeper to uncover the various facets of Insmed’s financial health.
Pros of Insmed’s Financials
Market Capitalization: With a market capitalization of approximately $11 billion, Insmed positions itself as a notable player within its industry. A high market cap often signals investor confidence and robust business potential.
Comments
Insmed (INSM) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Show more
Ratings data for INSM provided by MarketBeat
Insmed (INSM) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for INSM provided by MarketBeat
Insmed (INSM) had its price target raised by Wells Fargo & Company from $160.00 to $161.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for INSM provided by MarketBeat
News
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- Insmed said 12-month data from its TPIP open-label extension in pulmonary arterial hypertension showed sustained
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- Insmed defended the BRINSUPRI launch after investors worried about discontinuation rates, saying the drug’s $208